Simon Lichtiger
Overview
Explore the profile of Simon Lichtiger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
2125
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Verstockt B, Vermeire S, Peyrin-Biroulet L, Mosig R, Feagan B, Colombel J, et al.
J Crohns Colitis
. 2023 Nov;
18(5):762-772.
PMID: 37952114
Background And Aims: NX-13 activation of NLRX1 reduces intracellular reactive oxygen species and decreases inflammation in animal models of colitis. A phase 1a trial demonstrated a gut-selective pharmacokinetic profile with...
2.
Leber A, Hontecillas R, Tubau-Juni N, Lichtiger S, Bassaganya-Riera J
Inflamm Bowel Dis
. 2022 Apr;
28(12):1938.
PMID: 35489068
No abstract available.
3.
Leber A, Hontecillas R, Tubau-Juni N, Lichtiger S, Bassaganya-Riera J
Inflamm Bowel Dis
. 2022 Feb;
28(Suppl 1):S112.
PMID: 35104848
Background: Omilancor is an oral, once-daily, gut-restricted, small molecule, first-in-class therapeutic for Crohn's disease (CD) and ulcerative colitis (UC) that targets the novel LANCL2 pathway. Through LANCL2 activation, omilancor increases...
4.
Faye A, Oh A, Kumble L, Kiran R, Wen T, Lawlor G, et al.
Inflamm Bowel Dis
. 2019 Dec;
26(9):1368-1376.
PMID: 31880776
Background: Ileal pouch-anal anastomosis (IPAA) is the mainstay of surgical treatment for patients with ulcerative colitis (UC) but is associated with an increased risk of infertility. We developed a simulation...
5.
Faye A, Wen T, Ananthakrishnan A, Lichtiger S, Kaplan G, Friedman A, et al.
Clin Gastroenterol Hepatol
. 2019 Jul;
18(5):1133-1141.e3.
PMID: 31336196
Background & Aims: Patients with inflammatory bowel diseases (IBDs) have a high risk of venous thromboembolism (VTE). We assessed the timing and risk factors associated with readmission to the hospital...
6.
Lichtiger S
Gastrointest Endosc Clin N Am
. 2019 May;
29(3):xv-xvi.
PMID: 31078255
No abstract available.
7.
Axelrad J, Joelson A, Green P, Lawlor G, Lichtiger S, Cadwell K, et al.
Am J Gastroenterol
. 2018 Aug;
113(10):1530-1539.
PMID: 30072777
Objectives: Few studies have examined the role of non-Clostridium difficile enteric infections in flares of inflammatory bowel disease (IBD). Our objective was to investigate enteric infection detected by multiplex PCR...
8.
Nobel Y, Axelrad J, Lewis S, Whittier S, Lawlor G, Lichtiger S, et al.
Dig Dis Sci
. 2018 Feb;
63(4):996-1002.
PMID: 29411208
Background: Patients with celiac disease and inflammatory bowel disease, two immune-mediated luminal conditions, have higher rates of certain infections than healthy counterparts. The prevalence of many gastrointestinal infections in these...
9.
Axelrad J, Lichtiger S, Sethi A
Clin Gastroenterol Hepatol
. 2017 May;
16(3):A25-A26.
PMID: 28529163
No abstract available.
10.
Axelrad J, Joelson A, Nobel Y, Lawlor G, Green P, Lichtiger S, et al.
Inflamm Bowel Dis
. 2017 May;
23(6):1034-1039.
PMID: 28511200
Background: The similar presentations in relapse of inflammatory bowel disease (IBD) and enteric infection pose substantial barriers to diagnosis and treatment. The objective of this study was to investigate the...